The Two-Pronged Strategy

Intercept pursues two complementary approaches simultaneously:

Broad-Spectrum Preventatives (BSPs)

These are products—shots, pills, or nasal sprays—that work against many respiratory virus families at once (rhinoviruses, influenza, coronaviruses, etc.). Intercept’s stated target is a product that prevents more than 75% of symptomatic respiratory infections in as few doses as possible, with a realistic path to ~60% uptake .

Several candidates are already in or near human trials:

• INNA-051 — A once-weekly dry-powder nasal spray (TLR2/6 agonist) that boosts innate immunity in the nasal passages. It has secured $22.4 million and moved into Phase II trials . The University of Maryland’s Center for Vaccine Development launched a Phase II trial on June 24, 2026, testing this investigative spray .
• Q-Griffithsin (Q-GRFT) — A broad-spectrum antiviral nasal spray under study against coronaviruses, HIV, hepatitis C, and others (Phase I/II) .
• David Veesler’s group at University of Washington — Working on engineered virus-grabbing proteins that could be sprayed in the nose to catch pathogens before they infect .

Air-Cleaning Technologies (ACTs)

Intercept is also funding far-UVC light and advanced filtration systems for high-density indoor spaces—schools, offices, public transit. The goal is to reduce airborne viral load the way water treatment removed waterborne pathogens a century ago .

Neither BSPs nor ACTs alone can achieve elimination at realistic adoption rates. But their combined effect—analogous to fire-sprinkler coverage (~40% in U.S. commercial buildings) plus vaccines—could push viral reproduction numbers below 1 and dramatically cut transmission .

Why This Model? The Frontier Playbook

Intercept follows the same playbook Stripe pioneered with Frontier, a $1.8 billion advance-market commitment for carbon removal: use philanthropic capital to solve a problem that is technically possible but commercially unfunded . The Collison brothers have previously backed the Arc Institute ($650 million) and Fast Grants during COVID-19 .

This model is now being applied to pandemic preparedness and chronic infectious disease more broadly. OpenAI’s foundation, which received a $100 billion+ equity stake in the for-profit arm, committed $40.5 million in grants in 2025 . Billionaires including Dustin Moskovitz and Cari Tuna have donated over $20 billion to AI safety and global health .

A Broader Shift in Tech Philanthropy

Intercept is part of a wider movement where tech-sector philanthropists—frustrated by slow government funding and pharma’s focus on blockbuster drugs—are directly underwriting early-stage biomedical R&D and public-health infrastructure. The Pandemic Fund, a separate multilateral effort, has awarded $1.4 billion in grants to 128 countries for pandemic prevention, preparedness, and response . The Global Preparedness Monitoring Board’s 2025 report calls for a paradigm shift based on three imperatives: care, measure, and cooperate .

The bet behind Intercept is that catalytic philanthropic dollars can unlock markets where commercial incentives alone have failed—and that the next major public health breakthrough might come not from a lab in New Jersey, but from a tech billionaire’s portfolio.

The Two-Pronged Strategy

Intercept pursues two complementary approaches simultaneously:

Broad-Spectrum Preventatives (BSPs)

These are products—shots, pills, or nasal sprays—that work against many respiratory virus families at once (rhinoviruses, influenza, coronaviruses, etc.). Intercept’s stated target is a product that prevents more than 75% of symptomatic respiratory infections in as few doses as possible, with a realistic path to ~60% uptake .

Several candidates are already in or near human trials:

• INNA-051 — A once-weekly dry-powder nasal spray (TLR2/6 agonist) that boosts innate immunity in the nasal passages. It has secured $22.4 million and moved into Phase II trials . The University of Maryland’s Center for Vaccine Development launched a Phase II trial on June 24, 2026, testing this investigative spray .
• Q-Griffithsin (Q-GRFT) — A broad-spectrum antiviral nasal spray under study against coronaviruses, HIV, hepatitis C, and others (Phase I/II) .
• David Veesler’s group at University of Washington — Working on engineered virus-grabbing proteins that could be sprayed in the nose to catch pathogens before they infect .

Air-Cleaning Technologies (ACTs)

Intercept is also funding far-UVC light and advanced filtration systems for high-density indoor spaces—schools, offices, public transit. The goal is to reduce airborne viral load the way water treatment removed waterborne pathogens a century ago .

Neither BSPs nor ACTs alone can achieve elimination at realistic adoption rates. But their combined effect—analogous to fire-sprinkler coverage (~40% in U.S. commercial buildings) plus vaccines—could push viral reproduction numbers below 1 and dramatically cut transmission .

Why This Model? The Frontier Playbook

Intercept follows the same playbook Stripe pioneered with Frontier, a $1.8 billion advance-market commitment for carbon removal: use philanthropic capital to solve a problem that is technically possible but commercially unfunded . The Collison brothers have previously backed the Arc Institute ($650 million) and Fast Grants during COVID-19 .

This model is now being applied to pandemic preparedness and chronic infectious disease more broadly. OpenAI’s foundation, which received a $100 billion+ equity stake in the for-profit arm, committed $40.5 million in grants in 2025 . Billionaires including Dustin Moskovitz and Cari Tuna have donated over $20 billion to AI safety and global health .

A Broader Shift in Tech Philanthropy

Intercept is part of a wider movement where tech-sector philanthropists—frustrated by slow government funding and pharma’s focus on blockbuster drugs—are directly underwriting early-stage biomedical R&D and public-health infrastructure. The Pandemic Fund, a separate multilateral effort, has awarded $1.4 billion in grants to 128 countries for pandemic prevention, preparedness, and response . The Global Preparedness Monitoring Board’s 2025 report calls for a paradigm shift based on three imperatives: care, measure, and cooperate .

The bet behind Intercept is that catalytic philanthropic dollars can unlock markets where commercial incentives alone have failed—and that the next major public health breakthrough might come not from a lab in New Jersey, but from a tech billionaire’s portfolio.